The loss of RASSF1A is seen as a potential risk factor in IBC, with RIPK2 playing a regulatory role in tumor progression, Further studies show RIPK2’s involvement in metastasis and tumor growth, suggesting it could be a valuable prognostic marker and therapeutic target in IBC (Zare et al., 2018). This evidence concerns the gene RIPK2 and inflammatory breast carcinoma.